PIL have done a lot of prep work over several years, and are finally looking like they might have a better mousetrap. The company has hired a new CEO who has knowledge of and connections in the US healthcare market. Who knows where this one will go, but arthritis, and inflammation generally, is a huge potential market so might be worth a punt.

Disc, have a few, not worth much though.